Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Prime editing for the treatment of genetic diseases
Company stage: Pre-clinical
Genome editing tool: Prime editing
Funding stage: Private
Location: Cambridge, MA, USA
Gene editing partnerships: Beam Therapeutics
Prime Medicine is a start-up company that focuses on prime editing. Prime editing is a novel CRISPR-derived gene-editing technology, which was first disclosed in October 2019. Although the company has not revealed its first pre-clinical candidate, it launched with $315M in combined Series A and B funding. The company is co-founded by Professor David R. Liu, who also co-founded Editas Medicine, Beam Therapeutics, Pairwise Plants and Exo Therapeutics.